Coccidioidomycosis in persons infected with HIV-1

Research output: Chapter in Book/Report/Conference proceedingConference contribution

15 Citations (Scopus)

Abstract

Coccidioidomycosis is a recognized opportunistic infection in those with HIV-1 infection. The major risk factor is immunodeficiency, particularly when the peripheral blood CD4 T lymphocyte count is below 250/μL. There are many manifestations of coccidioidomycosis during HIV-1 infection, including diffuse, reticulonodular pneumonia, focal primary pneumonia, and disease disseminated beyond the thoracic cavity. Diagnosis is based on serology, culture and histopathologic identification. Two therapeutic modalities are currently available, the polyene antifungal amphotericin B and the triazole antifungals. Of the latter, the most experience is with the triazoles fluconazole and itraconazole. There are increasing data regarding drug interactions between triazoles and antiretroviral agents. The duration of treatment of coccidioidomycosis in those with HIV-1 infection is not established and in many patients it is either prolonged or life-long. Adherence to antiretroviral therapy is important in preventing recurrence.

Original languageEnglish (US)
Title of host publicationAnnals of the New York Academy of Sciences
Pages336-342
Number of pages7
Volume1111
DOIs
StatePublished - Sep 2007

Publication series

NameAnnals of the New York Academy of Sciences
Volume1111
ISSN (Print)00778923
ISSN (Electronic)17496632

Fingerprint

Coccidioidomycosis
Triazoles
HIV Infections
HIV-1
Pneumonia
Drug interactions
Anti-Retroviral Agents
Thoracic Cavity
Polyenes
Itraconazole
T-cells
Fluconazole
Opportunistic Infections
Amphotericin B
Serology
CD4 Lymphocyte Count
Drug Interactions
Blood
Therapeutics
T-Lymphocytes

Keywords

  • Coccidioidomycosis
  • HIV-1
  • Human

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Ampel, N. M. (2007). Coccidioidomycosis in persons infected with HIV-1. In Annals of the New York Academy of Sciences (Vol. 1111, pp. 336-342). (Annals of the New York Academy of Sciences; Vol. 1111). https://doi.org/10.1196/annals.1406.033

Coccidioidomycosis in persons infected with HIV-1. / Ampel, Neil M.

Annals of the New York Academy of Sciences. Vol. 1111 2007. p. 336-342 (Annals of the New York Academy of Sciences; Vol. 1111).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Ampel, NM 2007, Coccidioidomycosis in persons infected with HIV-1. in Annals of the New York Academy of Sciences. vol. 1111, Annals of the New York Academy of Sciences, vol. 1111, pp. 336-342. https://doi.org/10.1196/annals.1406.033
Ampel NM. Coccidioidomycosis in persons infected with HIV-1. In Annals of the New York Academy of Sciences. Vol. 1111. 2007. p. 336-342. (Annals of the New York Academy of Sciences). https://doi.org/10.1196/annals.1406.033
Ampel, Neil M. / Coccidioidomycosis in persons infected with HIV-1. Annals of the New York Academy of Sciences. Vol. 1111 2007. pp. 336-342 (Annals of the New York Academy of Sciences).
@inproceedings{095b48dbf06d4344bb796da429373fb1,
title = "Coccidioidomycosis in persons infected with HIV-1",
abstract = "Coccidioidomycosis is a recognized opportunistic infection in those with HIV-1 infection. The major risk factor is immunodeficiency, particularly when the peripheral blood CD4 T lymphocyte count is below 250/μL. There are many manifestations of coccidioidomycosis during HIV-1 infection, including diffuse, reticulonodular pneumonia, focal primary pneumonia, and disease disseminated beyond the thoracic cavity. Diagnosis is based on serology, culture and histopathologic identification. Two therapeutic modalities are currently available, the polyene antifungal amphotericin B and the triazole antifungals. Of the latter, the most experience is with the triazoles fluconazole and itraconazole. There are increasing data regarding drug interactions between triazoles and antiretroviral agents. The duration of treatment of coccidioidomycosis in those with HIV-1 infection is not established and in many patients it is either prolonged or life-long. Adherence to antiretroviral therapy is important in preventing recurrence.",
keywords = "Coccidioidomycosis, HIV-1, Human",
author = "Ampel, {Neil M.}",
year = "2007",
month = "9",
doi = "10.1196/annals.1406.033",
language = "English (US)",
isbn = "1573316881",
volume = "1111",
series = "Annals of the New York Academy of Sciences",
pages = "336--342",
booktitle = "Annals of the New York Academy of Sciences",

}

TY - GEN

T1 - Coccidioidomycosis in persons infected with HIV-1

AU - Ampel, Neil M.

PY - 2007/9

Y1 - 2007/9

N2 - Coccidioidomycosis is a recognized opportunistic infection in those with HIV-1 infection. The major risk factor is immunodeficiency, particularly when the peripheral blood CD4 T lymphocyte count is below 250/μL. There are many manifestations of coccidioidomycosis during HIV-1 infection, including diffuse, reticulonodular pneumonia, focal primary pneumonia, and disease disseminated beyond the thoracic cavity. Diagnosis is based on serology, culture and histopathologic identification. Two therapeutic modalities are currently available, the polyene antifungal amphotericin B and the triazole antifungals. Of the latter, the most experience is with the triazoles fluconazole and itraconazole. There are increasing data regarding drug interactions between triazoles and antiretroviral agents. The duration of treatment of coccidioidomycosis in those with HIV-1 infection is not established and in many patients it is either prolonged or life-long. Adherence to antiretroviral therapy is important in preventing recurrence.

AB - Coccidioidomycosis is a recognized opportunistic infection in those with HIV-1 infection. The major risk factor is immunodeficiency, particularly when the peripheral blood CD4 T lymphocyte count is below 250/μL. There are many manifestations of coccidioidomycosis during HIV-1 infection, including diffuse, reticulonodular pneumonia, focal primary pneumonia, and disease disseminated beyond the thoracic cavity. Diagnosis is based on serology, culture and histopathologic identification. Two therapeutic modalities are currently available, the polyene antifungal amphotericin B and the triazole antifungals. Of the latter, the most experience is with the triazoles fluconazole and itraconazole. There are increasing data regarding drug interactions between triazoles and antiretroviral agents. The duration of treatment of coccidioidomycosis in those with HIV-1 infection is not established and in many patients it is either prolonged or life-long. Adherence to antiretroviral therapy is important in preventing recurrence.

KW - Coccidioidomycosis

KW - HIV-1

KW - Human

UR - http://www.scopus.com/inward/record.url?scp=35348841488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348841488&partnerID=8YFLogxK

U2 - 10.1196/annals.1406.033

DO - 10.1196/annals.1406.033

M3 - Conference contribution

SN - 1573316881

SN - 9781573316880

VL - 1111

T3 - Annals of the New York Academy of Sciences

SP - 336

EP - 342

BT - Annals of the New York Academy of Sciences

ER -